Overview Dividends

(APLT) Applied Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03828A1016

Galactosemia, Diabetic Cardiomyopathy, Diabetic Neuropathy, Diabetic Retinopathy

APLT EPS (Earnings per Share)

EPS Growth (3Y CAGR): 9.85%
EPS Trend (3Y Correlation): 46.0%

APLT Revenue

Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): -27.1%

Description: APLT Applied Therapeutics October 19, 2025

Applied Therapeutics, Inc. (NASDAQ:APLT) is a clinical-stage biotech focused on novel therapeutics for high-unmet-need diseases in the U.S. Its lead candidate, AT-007, has finished Phase 3 trials in healthy adults for galactosemia and is now in a pediatric study, while also targeting sorbitol dehydrogenase deficiency and phosphomannomutase-CDG. The pipeline includes AT-001, in Phase 3 for diabetic cardiomyopathy and peripheral neuropathy, and AT-003, a preclinical program for diabetic retinopathy. The firm holds an exclusive license with Mercury Pharma Group to commercialize AT-007 and has been operating out of New York since its 2016 incorporation.

As of the latest 10-Q, APLT reported cash and cash equivalents of roughly $45 million, giving it an estimated 12-month runway at its current burn rate of $3-4 million per month. The biotech sector is currently benefiting from a 7 % YoY increase in R&D spending and a favorable FDA policy environment that has accelerated orphan-drug approvals, which could shorten time-to-market for AT-007 if it secures an orphan-drug designation. However, the company’s valuation is highly sensitive to Phase 3 readouts; a miss would likely depress the stock by 30-40 % based on historical outcomes for similar rare-disease programs.

For a deeper quantitative assessment, you might explore ValueRay’s analyst tools to model the potential impact of upcoming trial data on APLT’s valuation.

APLT Stock Overview

Market Cap in USD	128m
Sub-Industry	Biotechnology
IPO / Inception	2019-05-14

APLT Stock Ratings

Growth Rating	-29.9%
Fundamental	43.2%
Dividend Rating	-
Return 12m vs S&P 500	-93.3%
Analyst Rating	4.0 of 5

APLT Dividends

Currently no dividends paid

APLT Growth Ratios

Growth Correlation 3m	73.5%
Growth Correlation 12m	-31.5%
Growth Correlation 5y	-62.7%
CAGR 5y	1.74%
CAGR/Max DD 3y (Calmar Ratio)	0.02
CAGR/Mean DD 3y (Pain Ratio)	0.04
Sharpe Ratio 12m	-1.04
Alpha	-127.06
Beta	1.930
Volatility	133.24%
Current Volume	3374.6k
Average Volume 20d	2768.2k
Stop Loss	0.6 (-20%)
Signal	-0.45

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-67.7m TTM) > 0 and > 6% of Revenue (6% = 7260 TTM)

FCFTA -2.46 (>2.0%) and ΔFCFTA -188.5pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 13.9k% (prev 722.7%; Δ 13.1kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -2.46 (>3.0%) and CFO -91.8m <= Net Income -67.7m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.94 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (145.1m) change vs 12m ago 194.1% (target <= -2.0% for YES)

Gross Margin -71.90% (prev -56.73%; Δ -15.17pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 0.15% (prev 7.82%; Δ -7.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.55 (EBITDA TTM -78.2m / Interest Expense TTM -43.6m) >= 6 (WARN >= 3)

Altman Z'' -92.58

(A) 0.45 = (Total Current Assets 34.5m - Total Current Liabilities 17.7m) / Total Assets 37.3m

(B) -16.53 = Retained Earnings (Balance) -617.4m / Total Assets 37.3m

warn (B) unusual magnitude: -16.53 — check mapping/units

(D) -31.02 = Book Value of Equity -617.3m / Total Liabilities 19.9m

Total Rating: -92.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 43.16

1. Piotroski 0.50pt = -4.50

2. FCF Yield -91.44% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.15 = 2.49

5. Debt/Ebitda 0.36 = 2.40

7. RoE -231.6% = -2.50

8. Rev. Trend -27.09% = -2.03

9. EPS Trend 46.01% = 2.30

What is the price of APLT shares?

As of November 07, 2025, the stock is trading at USD 0.75 with a total of 3,374,566 shares traded.
Over the past week, the price has changed by -33.87%, over one month by -26.74%, over three months by +68.16% and over the past year by -92.26%.

Is Applied Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Applied Therapeutics (NASDAQ:APLT) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 43.16 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of APLT is around 0.72 USD . This means that APLT is currently overvalued and has a potential downside of -4%.

Is APLT a buy, sell or hold?

Applied Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy APLT.

Strong Buy: 2
Buy: 0
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the APLT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	3.2	322.7%
Analysts Target Price	3.2	322.7%
ValueRay Target Price	0.8	12%

APLT Fundamental Data Overview November 07, 2025

Market Cap USD = 128.2m (128.2m USD * 1.0 USD.USD)
P/S = 1059.3817
P/B = 7.7151
Beta = 1.93
Revenue TTM = 121.0k USD
EBIT TTM = -111.4m USD
EBITDA TTM = -78.2m USD
Long Term Debt = 2.60m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 447.0k USD (from shortTermDebt, last quarter)
Debt = 2.60m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -27.8m USD (from netDebt column, last quarter)
Enterprise Value = 100.4m USD (128.2m + Debt 2.60m - CCE 30.4m)
Interest Coverage Ratio = -2.55 (Ebit TTM -111.4m / Interest Expense TTM -43.6m)
FCF Yield = -91.44% (FCF TTM -91.8m / Enterprise Value 100.4m)
FCF Margin = -75.8k% (FCF TTM -91.8m / Revenue TTM 121.0k)
Net Margin = -56.0k% (Net Income TTM -67.7m / Revenue TTM 121.0k)
Gross Margin = -71.90% ((Revenue TTM 121.0k - Cost of Revenue TTM 208.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.69 (Enterprise Value 100.4m / Total Assets 37.3m)
Interest Expense / Debt = 27.71% (Interest Expense 721.0k / Debt 2.60m)
Taxrate = 21.0% (US default 21%)
NOPAT = -88.0m (EBIT -111.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.94 (Total Current Assets 34.5m / Total Current Liabilities 17.7m)
Debt / Equity = 0.15 (Debt 2.60m / totalStockholderEquity, last quarter 17.4m)
Debt / EBITDA = 0.36 (negative EBITDA) (Net Debt -27.8m / EBITDA -78.2m)
Debt / FCF = 0.30 (negative FCF - burning cash) (Net Debt -27.8m / FCF TTM -91.8m)
Total Stockholder Equity = 29.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -181.4% (out of range, set to none)
RoE = -231.6% (Net Income TTM -67.7m / Total Stockholder Equity 29.3m)
RoCE = -349.7% (out of range, set to none) (EBIT -111.4m / Capital Employed (Equity 29.3m + L.T.Debt 2.60m))
RoIC = -300.8% (out of range, set to none) (NOPAT -88.0m / Invested Capital 29.3m)
WACC = 13.84% (E(128.2m)/V(130.8m) * Re(13.68%) + D(2.60m)/V(130.8m) * Rd(27.71%) * (1-Tc(0.21)))
Discount Rate = 13.68% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 31.24%
Fair Price DCF = unknown (Cash Flow -91.8m)
EPS Correlation: 46.01 | EPS CAGR: 9.85% | SUE: 0.39 | # QB: 0
Revenue Correlation: -27.09 | Revenue CAGR: 0.0% | SUE: -0.08 | # QB: 0

Additional Sources for APLT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle